Interestingly, non-selective LRRK2 inhibitors were shown to protect against G2019S LRRK2-induced neurodegeneration in vivo (Liu et al., 2011), indicating that inhibition of LRRK2 activity may represent a valuable target in a PD therapeutic perspective. The gene discussed is LRRK2; the disease is Parkinson disease.